Wird geladen...
Developing EZH2 Targeted Therapy for Lung Cancer
Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown anti-tumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinomas models expressing high levels of EZH2 (1).
Gespeichert in:
| Veröffentlicht in: | Cancer Discov |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5012289/ https://ncbi.nlm.nih.gov/pubmed/27587466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0800 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|